Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 2/2017

27.09.2016 | Editorial Commentary

Predictive medicine: towards a multi-parametric imaging for a personal risk stratification

verfasst von: Eric Guedj, Serge Cammilleri, Antoine Verger

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

Ischemic stroke is a major public health issue with, per 100,000 persons, an incidence rate of 44-176, a disability-adjusted life-year of 80-597, and a mortality rate of 27-42 [1]. The total excess direct and indirect cost would correspond to €1.5 billion, only considering first-ever strokes [2]. Consequently, large financial offsets are expected, both in the healthcare sector and in the social service sector, if the incidence of stroke could be reduced. In this line, a study randomizing 3000 asymptomatic patients showed that successful carotid endarterectomy reduced 10-year stroke risks [3]. …
Literatur
1.
Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1(5):e259–281.CrossRef
2.
Ghatnekar O, Persson U, Glader E-L, Terént A. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care. 2004;20(3):375–80.CrossRef
3.
Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet Lond Engl. 2010;376(9746):1074–84.CrossRef
4.
Bang OY, Seok JM, Kim SG, Hong JM, Kim HY, Lee J, et al. Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol Seoul Korea. 2011;7(2):53–9.CrossRef
5.
Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand. 2009;119(1):1–16.CrossRef
6.
Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):2419–29.CrossRef
7.
Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, et al. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease. J Alzheimers Dis JAD. 2016.
8.
Jahae Kim, Kang-Ho Choi, Ho-Chun Song, Joon-Tae Kim; Man-Seok Park, Ki-Hyun Choi. 18F-FDG PET/CT imaging factors that predict ischemic stroke in cancer patients. Eur J Nucl Med. 2016.
9.
Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging. 2013;6(12):1250–9.CrossRef
10.
Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24.CrossRef
11.
Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012;71(5):709–18.CrossRef
12.
Kim H-J, Oh M, Moon DH, Yu K-H, Kwon SU, Kim JS, et al. Carotid inflammation on 18F-fluorodeoxyglucose positron emission tomography associates with recurrent ischemic lesions. J Neurol Sci. 2014;347(1–2):242–5.CrossRef
13.
Skagen K, Johnsrud K, Evensen K, Scott H, Krohg-Sørensen K, Reier-Nilsen F, et al. Carotid plaque inflammation assessed with (18)F-FDG PET/CT is higher in symptomatic compared with asymptomatic patients. Int J Stroke Off J Int Stroke Soc. 2015;10(5):730–6.CrossRef
14.
Rudd JHF, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11.CrossRef
15.
Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med Off Publ Soc Nucl Med. 2009;50(10):1611–20.
16.
Grandpierre S, Desandes E, Meneroux B, Djaballah W, Mandry D, Netter F, et al. Arterial foci of F-18 fluorodeoxyglucose are associated with an enhanced risk of subsequent ischemic stroke in cancer patients: a case-control pilot study. Clin Nucl Med. 2011;36(2):85–90.CrossRef
17.
Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, et al. Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med Off Publ Soc Nucl Med. 2002;43(5):658–63.
18.
Bonfiglioli R, Nanni C, Morigi JJ, Graziosi M, Trapani F, Bartoletti M, et al. 18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. Eur J Nucl Med Mol Imaging. 2013;40(8):1190–6.CrossRef
19.
Granados U, Fuster D, Pericas JM, Llopis J, Ninot S, Quintana E, et al. diagnostic accuracy of 18f-FDG PET/CT in infective endocarditis and implantable cardiac electronic device infection: a cross-sectional study. J Nucl Med Off Publ Soc Nucl Med. 2016.
20.
Anderson CM, Chang T, Graham MM, Marquardt MD, Button A, Smith BJ, et al. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys. 2015;91(3):472–9.CrossRef
21.
Houshmand S, Salavati A, Segtnan EA, Grupe P, Høilund-Carlsen PF, Alavi A. Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings. PET Clin. 2016;11(1):65–84.CrossRef
22.
Kwee RM, Truijman MTB, Mess WH, Teule GJJ, ter Berg JWM, Franke CL, et al. Potential of integrated [18F] fluorodeoxyglucose positron-emission tomography/CT in identifying vulnerable carotid plaques. AJNR Am J Neuroradiol. 2011;32(5):950–4.CrossRef
23.
Hyafil F, Schindler A, Sepp D, Obenhuber T, Bayer-Karpinska A, Boeckh-Behrens T, et al. High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging. Eur J Nucl Med Mol Imaging. 2016;43(2):270–9.CrossRef
24.
Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol. 2007;27(5):996–1003.CrossRef
25.
Fu L, Liu L, Zhang J, Xu B, Fan Y, Tian J. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. Eur Radiol. 2014;24(11):2800–9.CrossRef
26.
Visvikis D, Hatt M, Tixier F, Cheze Le Rest C. The age of reason for FDG PET image-derived indices. Eur J Nucl Med Mol Imaging. 2012;39(11):1670–2.CrossRef
27.
Fischer BM, Siegel BA, Weber WA, von Bremen K, Beyer T, Kalemis A. PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. Eur J Nucl Med Mol Imaging. 2016.
Metadaten
Titel
Predictive medicine: towards a multi-parametric imaging for a personal risk stratification
verfasst von
Eric Guedj
Serge Cammilleri
Antoine Verger
Publikationsdatum
27.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3522-2

Weitere Artikel der Ausgabe 2/2017

European Journal of Nuclear Medicine and Molecular Imaging 2/2017 Zur Ausgabe

Original Article

Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients

Original Article

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET

Letter to the Editor

The delicate balance between present and future

Erratum

Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

Original Article

The natural history of takotsubo syndrome: a two-year follow-up study with myocardial sympathetic and perfusion G-SPECT imaging

Image of the Month

68Ga-PSMA PET/CT with MRI fusion: spinal cord metastasis from prostate cancer